K Melissa Hallow
Overview
Explore the profile of K Melissa Hallow including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
177
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Mahato H, Ahlstrom C, Jansson-Lofmark R, Johansson U, Helmlinger G, Hallow K
NPJ Syst Biol Appl
. 2019 Mar;
5:9.
PMID: 30854224
[This corrects the article DOI: 10.1038/s41540-018-0077-9.].
12.
Mahato H, Ahlstrom C, Jansson-Lofmark R, Johansson U, Helmlinger G, Hallow K
NPJ Syst Biol Appl
. 2018 Dec;
5:2.
PMID: 30564457
Many preclinically promising therapies for diabetic kidney disease fail to provide efficacy in humans, reflecting limited quantitative translational understanding between rodent models and human disease. To quantitatively bridge interspecies differences,...
13.
Gebremichael Y, Lahu G, Vakilynejad M, Hallow K
J Pharmacokinet Pharmacodyn
. 2018 Nov;
46(1):15-25.
PMID: 30443840
Multiple classes of antihypertensive drugs inhibit components of the renin-angiotensin-aldosterone system (RAAS). The primary physiological effector of the RAAS is angiotensin II (AngII) bound to the AT1 receptor (AT1-bound AngII)....
14.
Hallow K, Greasley P, Helmlinger G, Chu L, Heerspink H, Boulton D
Am J Physiol Renal Physiol
. 2018 Jul;
315(5):F1295-F1306.
PMID: 30019930
The mechanisms of cardiovascular and renal protection observed in clinical trials of sodium-glucose cotransporter 2 (SGLT2) inhibitors (SGLT2i) are incompletely understood and likely multifactorial, including natriuretic, diuretic, and antihypertensive effects,...
15.
Brady J, Hallow K
J Clin Pharmacol
. 2017 Nov;
58(3):377-385.
PMID: 29144539
Sodium-glucose cotransporter 2 inhibitors (SGLT2i) reduce glucose levels in diabetes by inhibiting renal glucose reabsorption in the proximal tubule (PT), resulting in urinary glucose excretion. A recent large cardiovascular outcomes...
16.
Gebremichael Y, Lu J, Shankaran H, Helmlinger G, Mettetal J, Hallow K
Toxicol Sci
. 2017 Nov;
162(1):200-211.
PMID: 29126144
Drug-induced nephrotoxicity is a major cause of acute kidney injury, and thus detecting the potential for nephrotoxicity early in the drug development process is critical. Various urinary biomarkers exhibit different...
17.
Hallow K, Gebremichael Y, Helmlinger G, Vallon V
Am J Physiol Renal Physiol
. 2017 Feb;
312(5):F819-F835.
PMID: 28148531
Glomerular hypertension and hyperfiltration in early diabetes are associated with development and progression of diabetic kidney disease. The tubular hypothesis of diabetic hyperfiltration proposes that it is initiated by a...
18.
Van Brackle C, Harris R, Hallow K
J Appl Physiol (1985)
. 2016 Dec;
122(5):1292-1303.
PMID: 27979986
The brachial artery flow-mediated dilation (FMD) test is the most widely utilized method to evaluate endothelial function noninvasively in humans by calculating the percent change in diameter (FMD%). However, the...
19.
Hallow K, Lo A, Beh J, Rodrigo M, Ermakov S, Friedman S, et al.
Am J Physiol Regul Integr Comp Physiol
. 2014 Feb;
306(9):R647-62.
PMID: 24500431
Reproducibly differential responses to different classes of antihypertensive agents are observed among hypertensive patients and may be due to interindividual differences in hypertension pathology. Computational models provide a tool for...